ist scientific possibilities_200911_web-2
TRANSCRIPT
![Page 1: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/1.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
MediSapiens OyScientific possibilities of IST database
20. September 2011
![Page 2: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/2.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
Stratify your patients with thousands of others
Genomic signature for chromosomal instability
Hu
nd
red
s o
f p
atie
nts
High
Medium
Low
Data from your patiens?
Worst prognosis?
Resistant for therapy?
Best prognosis?
![Page 3: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/3.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
New therapy target for Ewing’s sarcoma?
![Page 4: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/4.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
Novel breast cancer associated gene
Only three publications in PubMed (none brca associated)
![Page 5: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/5.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
High ectopic expression in variety of cancers
![Page 6: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/6.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
Key EMT regulator and miRNA target in Brca
![Page 7: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/7.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
Nearly unknown MMP related gene
![Page 8: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/8.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
Known cell cycle player – new target for Burkitt’s lymphoma therapy?
![Page 9: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/9.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
Significant subsets of patients in multiple cancers for a known phosphatase downstream of KRAS
![Page 10: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/10.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
We have a patent pending algorithm* that enables you to compare your samples with over 15 000 fully annotated cancer samples.
Here we see three commonly used melanoma cell lines, and how their gene expression matches actual in vivo samples, with regards to melanoma specific genes.
* Kilpinen et al. BioData Mining 2011, 4:5 Ojala et. al. Genome Medicine, In Press
Are you sure your model actually models the cancer you study?
![Page 11: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/11.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • medisapiens.com
IST Online
![Page 12: Ist scientific possibilities_200911_web-2](https://reader031.vdocuments.mx/reader031/viewer/2022013121/554f564db4c905423f8b5570/html5/thumbnails/12.jpg)
Copyright © 2011 MediSapiens Ltd. All rights reserved. • www.medisapiens.com
MediSapiens Ltd.Biomedicum HelsinkiTukholmankatu 8AFIN-00290 Helsinki
+358 50 363 [email protected]